

Colorado HB 19-1131 Disclosure

Cystaran® (Cysteamine)

Leadiant Biosciences, Inc. ("Leadiant") provides the following information to Colorado prescribers, as required by Colorado House Bill 19-1131.

The pricing information below reflects Leadiant's Wholesale Acquisition Costs ("WAC") for their product: **Cystaran®**. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Cystaran®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Cystaran®	54482-0035-02	Ophthalmic Solution 0.44 %	\$2,856.70

Drug in the same therapeutic class as **Cystaran®** include:

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Cystadrops	55292-0410-05	Ophthalmic Solution 0.37%	\$2,654.99

For more information on the price disclosure requirements, please contact the Colorado State Board of Pharmacy at:

State Board of Pharmacy
1560 Broadway, Suite 1350
Denver, CO 80202
Ph. (303) 894-7800 | Fax: (303) 894-7692 | Email: dora_pharmacyboard@state.co.us

Cystaran® is a registered trademark of Leadiant.

Copyright© 2026 Leadiant All rights reserved.

07/10/2026